Ten companies traded in line with the broader market sentiment ... British pharmaceutical giant GSK plc (NYSE:GSK) saw its ...

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Drug company executives on Tuesday touted their industry’s work to keep and make Americans healthy during a Washington event.

GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...

Ten companies traded in line with the broader market sentiment ... British pharmaceutical giant GSK plc (NYSE:GSK) saw its share prices on Wednesday rise by 8.21 percent to finish at $37.70 ...

Vaccine sales declined 12%. GSK’s Specialty Medicines Drive Top Line HIV sales rose 14% during the quarter, driven by strong patient demand for the company’s two-drug regimens — Dovato and J ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.

GSK expects 2025 sales growth between 3% and ... with significant opportunities in second-line treatment. Analysts expressed concern over vaccine challenges, particularly Arexvy's short-term ...

GSK's annual revenues were held back weak vaccines sales, but shares in the pharma giant jumped on Wednesday after the ...